(8) To exclude costs related to the CIMA LABS restructuring announced in January 2008.
(9) To exclude charges related to the acquisition of licensed technology in the oncology field.
(10) To reflect the tax effect of pre-tax adjustments at the applicable
tax rates and certain other tax adjustments primarily related to changes in
valuation allowances, the settlement of the investigations by the U.S.
Attorney's Office and other changes in tax assets and liabilities. The 2008
amount includes $84.5 million of tax benefits for the settlement with the
U.S. Attorney's Office, for which the related expense was recorded in 2007
and for the states of Connecticut and Massachusetts, for which the related
expense was recorded in the third quarter of 2008.
CEPHALON, INC. AND SUBSIDIARIES
CONSOLIDATED SALES DETAIL
Three Months Ended
States Europe Total
PROVIGIL $241,366 $17,793 259,159
GABITRIL 12,176 2,337 14,513
CNS 253,542 20,130 273,672
ACTIQ 21,392 14,401 35,793
Generic OTFC 19,569 - 19,569
FENTORA 41,330 - 41,330
AMRIX 20,512 - 20,512
|SOURCE Cephalon, Inc.|
Copyright©2008 PR Newswire.
All rights reserved